JP2019528781A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528781A5 JP2019528781A5 JP2019531572A JP2019531572A JP2019528781A5 JP 2019528781 A5 JP2019528781 A5 JP 2019528781A5 JP 2019531572 A JP2019531572 A JP 2019531572A JP 2019531572 A JP2019531572 A JP 2019531572A JP 2019528781 A5 JP2019528781 A5 JP 2019528781A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- polypeptide
- light
- isolated
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims description 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 29
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 29
- 210000004027 cell Anatomy 0.000 claims description 20
- 150000007523 nucleic acids Chemical class 0.000 claims description 15
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 102000004310 Ion Channels Human genes 0.000 claims description 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 238000012986 modification Methods 0.000 claims description 6
- 230000004048 modification Effects 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 210000000411 amacrine cell Anatomy 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 210000000170 cell membrane Anatomy 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 210000003994 retinal ganglion cell Anatomy 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 210000002287 horizontal cell Anatomy 0.000 claims description 2
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 108091008695 photoreceptors Proteins 0.000 claims description 2
- 210000002508 rod bipolar cell Anatomy 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 208000003098 Ganglion Cysts Diseases 0.000 claims 1
- 208000005400 Synovial Cyst Diseases 0.000 claims 1
- 210000003569 retinal bipolar cell Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 15
- 108090000862 Ion Channels Proteins 0.000 description 5
- 239000012528 membrane Substances 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 108010035848 Channelrhodopsins Proteins 0.000 description 3
- 206010034972 Photosensitivity reaction Diseases 0.000 description 3
- 230000036211 photosensitivity Effects 0.000 description 3
- 230000004304 visual acuity Effects 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 2
- 102220499768 Carbonic anhydrase 2_H94Q_mutation Human genes 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 230000010370 hearing loss Effects 0.000 description 2
- 231100000888 hearing loss Toxicity 0.000 description 2
- 208000016354 hearing loss disease Diseases 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000001116 retinal neuron Anatomy 0.000 description 2
- 102220160825 rs202001245 Human genes 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000003040 circulating cell Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 102200149714 rs113604459 Human genes 0.000 description 1
- 102200063449 rs41298432 Human genes 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000000857 visual cortex Anatomy 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662380871P | 2016-08-29 | 2016-08-29 | |
| US62/380,871 | 2016-08-29 | ||
| PCT/US2017/049158 WO2018044912A1 (en) | 2016-08-29 | 2017-08-29 | Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019528781A JP2019528781A (ja) | 2019-10-17 |
| JP2019528781A5 true JP2019528781A5 (https=) | 2020-09-24 |
| JP7116884B2 JP7116884B2 (ja) | 2022-08-12 |
Family
ID=59859616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531572A Active JP7116884B2 (ja) | 2016-08-29 | 2017-08-29 | 改善された光感受性を有するチャネルオプシン変異体における突然変異の特定及びその使用方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11041004B2 (https=) |
| EP (1) | EP3504227A1 (https=) |
| JP (1) | JP7116884B2 (https=) |
| KR (3) | KR102609571B1 (https=) |
| CN (2) | CN110023327B (https=) |
| AU (4) | AU2017319306B2 (https=) |
| BR (1) | BR112019003950A2 (https=) |
| CA (1) | CA3034887A1 (https=) |
| IL (2) | IL265010B2 (https=) |
| MX (1) | MX2019002321A (https=) |
| MY (1) | MY197491A (https=) |
| NZ (1) | NZ751983A (https=) |
| RU (1) | RU2019109021A (https=) |
| SG (2) | SG10202102061SA (https=) |
| WO (1) | WO2018044912A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3504227A1 (en) | 2016-08-29 | 2019-07-03 | Wayne State University | Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof |
| CN113173984B (zh) | 2021-04-12 | 2022-08-30 | 中眸医疗科技(武汉)有限公司 | 一种新型光敏感通道蛋白vr1.0在制备视网膜感光细胞退行性疾病药物中的应用 |
| MX2024007770A (es) * | 2021-12-20 | 2024-07-01 | Genans Biotechnology Co Ltd | Restauracion visual optogenetica utilizando neuropsina acoplada a gq sensible a la luz (opsin 5). |
| EP4665750A1 (en) | 2023-02-17 | 2025-12-24 | Ray Therapeutics, Inc. | Gene therapy compositions and methods for treating diseases of the retina |
| WO2025137649A1 (en) * | 2023-12-22 | 2025-06-26 | Wayne State University | Method of enhancing viral mediated gene delivery |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| IE913929A1 (en) | 1990-11-13 | 1992-05-20 | Immunex Corp | Bifunctional selectable fusion genes |
| AU6953394A (en) | 1993-05-21 | 1994-12-20 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| EP0745134A1 (en) | 1994-02-22 | 1996-12-04 | Danafarber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
| EP1919497B1 (en) | 2005-07-22 | 2020-02-12 | The Board of Trustees of the Leland Stanford Junior University | Light-activated cation channel and uses thereof |
| CN101484005A (zh) | 2006-05-04 | 2009-07-15 | 韦恩州立大学 | 通过向体内递送视紫红质核酸恢复视觉响应 |
| KR100922422B1 (ko) | 2006-06-27 | 2009-10-16 | 가부시키가이샤 어드밴테스트 | 반도체 시험 장치 및 반도체 메모리의 시험 방법 |
| WO2011140279A1 (en) | 2010-05-04 | 2011-11-10 | Wayne State University | Aav-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells |
| KR101945962B1 (ko) | 2010-09-08 | 2019-02-08 | 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. | 돌연변이 채널로돕신 2 |
| CN105755044A (zh) | 2011-04-22 | 2016-07-13 | 加利福尼亚大学董事会 | 具有变异衣壳的腺相关病毒病毒体及其使用方法 |
| WO2013071231A1 (en) * | 2011-11-12 | 2013-05-16 | Massachusetts Institute Of Technology | Channelrhodopsins for optical control of cells |
| CA2866405A1 (en) * | 2012-03-05 | 2013-09-12 | Wayne State University | Identification of channelopsin-2 (chop2) mutations and methods of use |
| EP2968476B1 (en) * | 2013-03-14 | 2021-05-05 | Wayne State University | A plasmin for use in enhancing delivery of therapeutic compounds to the eyes or for improving vision |
| EP3102290A1 (en) * | 2014-02-07 | 2016-12-14 | Massachusetts Institute Of Technology | Blue light-activated ion channel molecules and uses thereof |
| EP4678754A3 (en) | 2014-03-11 | 2026-04-08 | Wayne State University | A modified mglur6 promoter and methods of use |
| WO2015161308A1 (en) | 2014-04-18 | 2015-10-22 | Massachusetts Institute Of Technology | Mutant channelrhodopsins with altered ion selectivity |
| WO2016179038A1 (en) | 2015-05-01 | 2016-11-10 | Spark Therapeutics, Inc. | ADENO-ASSOCIATED VIRUS-MEDIATED CRISPR-Cas9 TREATMENT OF OCULAR DISEASE |
| LT3436051T (lt) | 2016-03-31 | 2021-11-25 | Spark Therapeutics, Inc. | Kolonėlėmis pagrįstas visiškai keičiamo masto raav gavimo būdas |
| WO2017210664A1 (en) | 2016-06-03 | 2017-12-07 | Massachusetts Institute Of Technology | Somatic opsins for single cell resolution optogenetics |
| AU2017302013B2 (en) | 2016-07-29 | 2022-05-26 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| EP3504227A1 (en) | 2016-08-29 | 2019-07-03 | Wayne State University | Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof |
-
2017
- 2017-08-29 EP EP17767952.9A patent/EP3504227A1/en active Pending
- 2017-08-29 SG SG10202102061SA patent/SG10202102061SA/en unknown
- 2017-08-29 MX MX2019002321A patent/MX2019002321A/es unknown
- 2017-08-29 CN CN201780060143.3A patent/CN110023327B/zh active Active
- 2017-08-29 AU AU2017319306A patent/AU2017319306B2/en active Active
- 2017-08-29 KR KR1020197008895A patent/KR102609571B1/ko active Active
- 2017-08-29 MY MYPI2019001044A patent/MY197491A/en unknown
- 2017-08-29 IL IL265010A patent/IL265010B2/en unknown
- 2017-08-29 JP JP2019531572A patent/JP7116884B2/ja active Active
- 2017-08-29 SG SG11201901697QA patent/SG11201901697QA/en unknown
- 2017-08-29 RU RU2019109021A patent/RU2019109021A/ru unknown
- 2017-08-29 CA CA3034887A patent/CA3034887A1/en active Pending
- 2017-08-29 WO PCT/US2017/049158 patent/WO2018044912A1/en not_active Ceased
- 2017-08-29 KR KR1020237041296A patent/KR102877327B1/ko active Active
- 2017-08-29 IL IL310142A patent/IL310142A/en unknown
- 2017-08-29 US US16/328,916 patent/US11041004B2/en active Active
- 2017-08-29 KR KR1020257035361A patent/KR20250159068A/ko active Pending
- 2017-08-29 CN CN202410173021.7A patent/CN119979612A/zh active Pending
- 2017-08-29 NZ NZ751983A patent/NZ751983A/en unknown
- 2017-08-29 BR BR112019003950-3A patent/BR112019003950A2/pt unknown
-
2021
- 2021-05-19 US US17/324,501 patent/US12234267B2/en active Active
-
2022
- 2022-02-25 AU AU2022201291A patent/AU2022201291B2/en active Active
-
2024
- 2024-01-02 AU AU2024200016A patent/AU2024200016B9/en active Active
-
2025
- 2025-01-16 US US19/025,068 patent/US20250163111A1/en active Pending
- 2025-10-13 AU AU2025248765A patent/AU2025248765A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019528781A5 (https=) | ||
| AU2021245195B2 (en) | Identification of Channelopsin-2 (Chop2) mutations and methods of use | |
| Pan et al. | Optogenetic approaches to restoring vision | |
| Duebel et al. | Optogenetics | |
| KR102008538B1 (ko) | 감광성 키메라 gpcr 단백질 | |
| RU2019109021A (ru) | Идентификация мутаций в вариантах каналопсина, имеющих улучшенную чувствительность к свету, и способы их применения | |
| De Silva et al. | Optogenetic approaches to therapy for inherited retinal degenerations | |
| BR112016019432B1 (pt) | Composição terapêutica, kit e seus usos na terapia gênica contra degeneração da retina | |
| MX2010012592A (es) | Vectores para la administracion de proteinas sensibles a la luz y metodos de uso de las mismas. | |
| JP2009536219A5 (https=) | ||
| Parnami et al. | Current approaches to vision restoration using optogenetic therapy | |
| Tochitsky et al. | Optopharmacological tools for restoring visual function in degenerative retinal diseases | |
| Provansal et al. | Vision restoration by optogenetic therapy and developments toward sonogenetic therapy | |
| JP7492777B2 (ja) | 光応答性タンパク質及びその利用 | |
| Douar et al. | 268. Optogenetic engineering of retinal ganglion cells with AAV2. 7m8-ChrimsonR-tdTomato (GS030-DP) is well tolerated and induces functional responses to light in non-human primates | |
| US12459977B2 (en) | Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof | |
| CN112010952A (zh) | 光敏感通道ChR2蛋白的突变体及其应用 | |
| WO2021182646A1 (ja) | 色認識のための光応答性タンパク質及びその利用 | |
| Kwan et al. | Hybrid optogenetic and electrical stimulation of retinal ganglion cells for artificial vision | |
| Kleinlogel et al. | Physiological Reviews Review Article | |
| Tochitsky | Photochemical control of neuronal activity: methods and clinical application | |
| HK1205744B (en) | Identification of channelrhodopsin-2 (chop2) mutations and methods of use | |
| Shen et al. | MP Simunovic1, 2 MB BChir PhD FRANZCO | |
| ZHANG et al. | Advances of optogenetics in the treatment of retinitis pigmentosa | |
| Gauvain et al. | 24 A Promise of Vision Restoration |